MDXG logo

MiMedx Group Inc (MDXG)

$3.74

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MDXG

Market cap

$545144150

EPS

--

P/E ratio

116.7

Price to sales

1.92

Dividend yield

--

Beta

1.173477

Price on MDXG

Previous close

$4.23

Today's open

$4.20

Day's range

$3.73 - $4.20

52 week range

$3.03 - $7.97

Profile about MDXG

CEO

Joseph H. Capper

Employees

837

Headquarters

Marietta, GA

Exchange

NASDAQ Capital Market

Shares outstanding

145760468

Issue type

Common Stock

MDXG industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MDXG

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

news source

GlobeNewsWire • Oct 14, 2026

news preview

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product

news source

GlobeNewsWire • Sep 23, 2026

news preview

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this consi.

news source

Business Wire • Sep 10, 2026

news preview

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

news source

GlobeNewsWire • Sep 8, 2026

news preview

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Jul 30, 2026

news preview

MiMedx Group Q2 Earnings Call Highlights

MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx's second-quarter results, which showed sequential improvement in its wound-care business and continued growth in surgical sales.

news source

MarketBeat • Jul 29, 2026

news preview

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

Reports  Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026.

news source

GlobeNewsWire • Jul 29, 2026

news preview

MIMEDX to Acquire Sanara MedTech

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX's Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX's Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga. and FORT WORTH, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Sanara MedTech Inc. (“Sanara,” “Sanara MedTech”) (Nasdaq: SMTI) today announced that they have entered into a definitive merger agreement under which MIMEDX will acquire all of the outstanding shares of Sanara in a cash and stock transaction valued at $35 per Sanara share with a total enterprise value of approximately $350 million.

news source

GlobeNewsWire • Jul 29, 2026

news preview

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026.

news source

GlobeNewsWire • Jul 20, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext.

news source

PRNewsWire • May 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MiMedx Group Inc

Open an M1 investment account to buy and sell MiMedx Group Inc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MDXG on M1